A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2, multi-center study in which patients will receive KZR-616, administered
as a subcutaneous (SC) injection weekly for 13 weeks (Phase 1b) or 24 weeks (Phase 2).